FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Cupric Sulfate Not Withdrawn Due to Safety/Efficacy

[ Price : $8.95]

Federal Register notice: FDA determines that Abraxis Pharmaceuticals cupric sulfate injection was not withdrawn from sale for reas...

Pharma Science/Clin Pharm Panel Renewed

[ Price : $8.95]

Federal Register notice: FDA renews the charter of its Pharmaceutical Science and Clinical Pharmacology Advisory Committee for an ...

Guide on Postmarketing Safety eSubmissions

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance entitled Providing Submissions in Electronic Format Postmarketing S...

MDIC Device External Evidence Framework

[ Price : $8.95]

The Medical Device Innovation Consortium publishes its framework on external evidence methods for medical devices based on input f...

Simulations Plus Finishes FDA Project

[ Price : $8.95]

Simulations Plus completes an FDA-funded project for a model-integrated design for bioequivalence studies in long-acting injectabl...

FDA Wants Authority to Require Superiority Data in NDAs

[ Price : $8.95]

FDA commissioner Robert Califf says the agency is considering asking Congress for additional authority to have the option of requi...

BIO Comments on Pediatric Cancer Drug Docket

[ Price : $8.95]

The Biotechnology Innovation Organization suggests ways for FDA to create a conceptual framework to inform decision-making for ped...

Moderna Seeks Vaccine EUA for Kids 6 Months to 6 Years

[ Price : $8.95]

Moderna is asking FDA for an emergency use authorization for its Covid-19 vaccine in children aged 6 months to 6 years old.

Lillys Tirzepatide Meets Trial Weight Loss Endpoints

[ Price : $8.95]

Lilly says its investigational weight-loss drug tirzepatide met all endpoints in the 72-week SURMOUNT-1 trial.

FDA Lifts Hold on Pfizer Duchenne Gene Therapy

[ Price : $8.95]

FDA lifts a clinical hold on Pfizers mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duche...